B. Riley analyst Mayank Mamtani raised the firm’s price target on TG Therapeutics to $23 from $17 and keeps a Buy rating on the shares after the FDA approved Briumvi for the treatment of relapsing forms of multiple sclerosis.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TGTX: